Drugmaker Alexion to buy biotech Achillion in $930 mln deal
Alexion's offer of $6.30 per share represents a premium of 72.6 per cent to Achillion stock's close
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.